Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
111 hedge funds and large institutions have $67.2M invested in Sanofi Contingent Value Rights in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 12 closing their positions.
16% more capital invested
Capital invested by funds: $58.1M → $67.2M (+$9.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 120 → 111 (-9)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$588K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$543K |
| 3 |
AMH
Apollo Management Holdings
New York
|
+$55.3K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$43.9K |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$28.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$1.76M |
| 2 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$439K |
| 3 |
Millennium Management
New York
|
-$110K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
-$91.6K |
| 5 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$79.1K |
GCVRZ Hedge Fund Activity: Q1 2017 in Review
111 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2017, worth a combined $67.2M — up 16% from $58.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GCVRZ and 8 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 14 added.
The largest buyer was Stonehill Capital Management, adding an estimated $588K. The largest seller was Whitebox Advisors, cutting an estimated $1.76M.
- 111 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2017, down from 120 in Q4 2016.
- Funds reported $67.2M of Sanofi Contingent Value Rights stock for Q1 2017, up 16% quarter-over-quarter.
- 8 funds opened new Sanofi Contingent Value Rights positions in Q1 2017 and 12 closed out, a net change of -4 holders.
- The largest Sanofi Contingent Value Rights buyer in Q1 2017 was Stonehill Capital Management, an estimated $588K added.
- The largest Sanofi Contingent Value Rights seller in Q1 2017 was Whitebox Advisors, an estimated $1.76M sold.
Based on aggregated 13F filings for Q1 2017.